| Added by | tchardes |
|---|---|
| Group name | EquipeELC |
| Item Type | Journal Article |
| Title | Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures |
| Creator | Larbouret et al. |
| Author | Christel Larbouret |
| Author | Laurent Gros |
| Author | André Pèlegrin |
| Author | Thierry Chardès |
| Abstract | Monoclonal antibodies have revolutionized the treatment of many diseases, but their clinical efficacy remains limited in some other cases. Pre-clinical and clinical trials have shown that combinations of antibodies that bind to the same target (homo-combinations) or to different targets (hetero-combinations) to mimic the polyclonal humoral immune response improve their therapeutic effects in cancer. The approval of the trastuzumab/pertuzumab combination for breast cancer and then of the ipilimumab/nivolumab combination for melanoma opened the way to novel antibody combinations or oligoclonal antibody mixtures as more effective biologics for cancer management. We found more than 300 phase II/III clinical trials on antibody combinations, with/without chemotherapy, radiotherapy, small molecules or vaccines, in the ClinicalTrials.gov database. Such combinations enhance the biological responses and bypass the resistance mechanisms observed with antibody monotherapy. Usually, such antibody combinations are administered sequentially as separate formulations. Combined formulations have also been developed in which separately produced antibodies are mixed before administration or are produced simultaneously in a single cell line or a single batch of different cell lines as a polyclonal master cell bank. The regulation, toxicity and injection sequence of these oligoclonal antibody mixtures still need to be addressed in order to optimize their delivery and their therapeutic effects. |
| Publication | Cancers |
| Volume | 13 |
| Issue | 18 |
| Pages | 4620 |
| Date | 2021-09-15 |
| Journal Abbr | Cancers (Basel) |
| Language | eng |
| DOI | 10.3390/cancers13184620 |
| ISSN | 2072-6694 |
| Short Title | Improving Biologics' Effectiveness in Clinical Oncology |
| Library Catalog | PubMed |
| Extra | PMID: 34572847 |
| Tags | antibody, biologic, cancer, cnrs, combination, first-last-corresponding, mabimprove, mixture, monoclonal antibody, oligoclonal, review |
| Date Added | 2021/10/01 - 17:23:07 |
| Date Modified | 2023/04/06 - 16:50:41 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
